Abstract:Background Vascular injury results in uncontrollable hemorrhage in hemorrhagic diseases and excessive antithrombotic therapy. Safe and efficient hemostatic agents which can be orally administered are urgently needed. Platelets play indispensable roles in hemostasis, but there is no drug exerting hemostatic effects through enhancing platelet function. Methods The regulatory effects of icaritin, a natural compound isolated from Herba Epimedii , on the dense granule release, thromboxane A 2 (TxA 2 ) synthesis, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by multiple agonists were investigated. The effects of icaritin on tail vein bleeding times of warfarin-treated mice were also evaluated. Furthermore, we investigated the underlying mechanisms by which icaritin exerted its pharmacological effects. Results Icaritin alone did not activate platelets, but significantly potentiated the dense granule release, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by thrombin and U46619. Icaritin also shortened tail vein bleeding times of mice treated with warfarin. In addition, phosphorylated proteome analysis, immunoblotting analysis, and pharmacological research revealed that icaritin sensitized the activation of phospholipase Cγ2 (PLCγ2)-protein kinase C (PKC) signaling pathways, which play important roles in platelet activation. Conclusion Icaritin can sensitize platelet activation induced by thrombin and TxA 2 through enhancing the activation of PLCγ2-PKC signaling pathways and promote hemostasis, and has potential to be developed into a novel orally deliverable therapeutic agent for hemorrhages. The datasets analyzed for the current study are available from the corresponding author on request. Z.Z., Y.L., H.L., R.G., D.H., Z.L., M.H., C.S., J.Y., and K.Z. performed most of the experiments, and contributed to the acquisition and analysis of data. Z.Z. designed the study and drafted the manuscript. N.W. contributed to the analysis of data and revised the manuscript. P.T. and G.Z. supervised the study team and revised the manuscript. Received: 03 April 2023 Accepted: 13 January 2024 Accepted Manuscript online: 15 January 2024 Article published online: 09 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Novel GPIb-independent platelet aggregation induced by botrocetin: Implications for diagnosis and antithrombotic therapy

Experimental Study of Interaction Between Activated VWF and Targeted Lipid Microbubbles Conjugated with Recombinant GPIba

Experimental study of interaction between activated VWF and targeted lipid microbubbles conjugated with recombinant GPⅠba

In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα

Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

Dual roles of fucoidan-GPIbα interaction in thrombosis and hemostasis: implications for drug development targeting GPIbα

Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Icaritin Sensitizes Thrombin- and TxA2-Induced Platelet Activation and Promotes Hemostasis via Enhancing PLCγ2-PKC Signaling Pathways

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

Engineering and Characterization of a Chimeric Anti-platelet Glycoprotein Ibα Monoclonal Antibody and Preparation of Its Fab Fragment

Synergic Effect Of Gpiba And Von Willebrand Factor In Pathogenesis Of Deep Vein Thrombosis

Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure

Mechanisms of Αiibβ3 Biogenesis in the Megakaryocyte: A Proteomics Approach

Essential role of glycoprotein Ibα in platelet activation

Platelet integrin αIIbβ3 plays a key role in venous thrombogenesis in a mouse model

Physiological platelet aggregation assay to mitigate drug-induced thrombocytopenia using a microphysiological system

From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks